Ipsen to Present Improvements to Somatuline® Autogel® Pre-filled Syringe at the 16th European Neuroendocrine Tumor Society (ENETS) Annual Conference

 

ENETS abstract coincides with first European launch

 

 

Paris (France), 6 March 2019 Ipsen (Euronext: IPN; ADR: IPSEY) today simultaneously announced the EU launch of a new pre-filled syringe for Somatuline® Autogel® (lanreotide) for patients with neuroendocrine tumors (NETs), acromegaly or symptoms associated with carcinoid syndrome, and released findings from the human factor studies that underpinned its development as a poster presentation (Abstract #H14) at ENETS 2019.1,2 As of April 2019, patients in Ireland will be the first to benefit from the new ready-to-use, pre-filled syringe. Ipsen has confirmed they are committed to making this new pre-filled syringe available to patients and healthcare professionals throughout Europe, the U.S., Canada, Australia and New Zealand during 2019 following necessary regulatory approvals.

The new pre-filled syringe for Somatuline® Autogel® was the result of several studies, involving patients, their caregivers, nurses and other healthcare professionals, to inform and test enhancements to the existing pre-filled syringe.1 Notable new features are modified ergonomics and handling, a needle shield removal system, an injection process with plunger support and heightened ease of use.1 The automatic, built-in safety system, which helps to prevent needle stick injury by locking in place following the administration, has not been changed.

 

Today’s announcement around the EU launch of a new pre-filled syringe for Somatuline® Autogel® is not only an important new option for patients living with acromegaly and NETs but represents a significant milestone in our commitment to patient-centric innovation,” said Bartek Bednarz, Senior Vice President, Global Oncology Franchise at Ipsen. “We are also proud to be sharing as a poster presentation at ENETS 2019 the results of several studies, where we tested, evolved and validated changes for every stage of the Somatuline® Autogel® injection experience”, added Sotirios Stergiopoulos, Chief Medical Officer at Ipsen.

 

“NETs and acromegaly can be associated with a number of uncomfortable and unpleasant symptoms, so any innovation that eases the physical challenges of treatment for the patient and their healthcare team is a step forward,” said Daphne T Adelman, Clinical Nurse Specialist from Northwestern University in Chicago, U.S. and one of the authors of the study.

© Ipsen Pharma, 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France. All rights reserved. - 2019